T 502
Alternative Names: Mannan-conjugated allergoids of birch pollen allergens - Inmunotek; T 502Latest Information Update: 10 Sep 2025
At a glance
- Originator Inmunotek
- Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 27 Jun 2025 Inmunotek completes a phase III trial in Allergic rhinitis (In adolescents, In adults) in Germany (SC) (CTIS2024-515717-17-00)
- 27 Jun 2025 Inmunotek completes a phase III trial in Allergic rhinoconjuctivitis (In adolescents, In adults) in Germany (SC) (CTIS2024-515717-17-00)
- 28 Oct 2024 Phase-III clinical trials in Allergic rhinitis (In adolescents, In adults) in Germany (SC) (CTIS2024-515717-17-00)